-
![N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-YL)-1,3-thiazol-4-YL] amides](/abs-image/US/2018/10/30/US10112958B2/abs.jpg.150x150.jpg)
公开(公告)号：US10112958B2
公开(公告)日：2018-10-30
申请号：US15646572
申请日：2017-07-11
Applicant: Pfizer Inc.
Inventor： Michael Aaron Brodney , Christopher Ryan Butler , Lei Zhang , Brian Thomas O'Neill , Patrick Robert Verhoest , Peter Justin Mikochik , John Charles Murray , Xinjun Hou
IPC: C07D513/04 , C07D513/10 , C07D513/20
Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US20240150334A1
公开(公告)日：2024-05-09
申请号：US18482129
申请日：2023-10-06
Applicant: Pfizer Inc.
Inventor： Jan Antoinette Cusi Romero Adams , Bruce Michael Bechle , Jason Kenneth Dutra , Michelle Renee Garnsey , Xinjun Hou , Jisun Lee , Deane Milford Nason, II , Steven Victor O'Neil , Danica Antonia Rankic , Yang Wang , Ann Sorrentino Wright , Lei Zhang , Liying Zhang , David James Edmonds
IPC: C07D413/04 , C07D231/56 , C07D263/56 , C07D401/04 , C07D403/04 , C07D405/14 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04 , C07D491/048 , C07D498/04 , C07D513/04
CPC classification number: C07D413/04 , C07D231/56 , C07D263/56 , C07D401/04 , C07D403/04 , C07D405/14 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04 , C07D491/048 , C07D498/04 , C07D513/04
Abstract: Described herein are compounds of Formula I,
wherein the variables are defined herein, their use as HSD17B13 inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, NAFLD and NASH.-
Patent Agency Ranking
![N-[2-(2-AMINO-6,6-DISUBSTITUTED-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL)-1,3-THIAZOL-4-YL] AMIDES](/abs-image/US/2017/10/26/US20170305931A1/abs.jpg.150x150.jpg)
3.发明申请公开(公告)号：US20170305931A1
公开(公告)日：2017-10-26
申请号：US15646572
申请日：2017-07-11
Applicant: Pfizer Inc.
Inventor： Michael Aaron Brodney , Christopher Ryan Butler , Lei Zhang , Brian Thomas O'Neill , Patrick Robert Verhoest , Peter Justin Mikochik , John Charles Murray , Xinjun Hou
IPC: C07D513/04 , C07D513/20 , C07D513/10
CPC classification number: C07D513/04 , C07D513/10 , C07D513/20
Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
![N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl)-1,3-thiazol-4-yl]amides](/abs-image/US/2017/09/05/US09751895B2/abs.jpg.150x150.jpg)
公开(公告)号：US09751895B2
公开(公告)日：2017-09-05
申请号：US15272501
申请日：2016-09-22
Applicant: Pfizer Inc.
Inventor： Michael Aaron Brodney , Christopher Ryan Butler , Lei Zhang , Brian Thomas O'Neill , Patrick Robert Verhoest , Peter Justin Mikochik , John Charles Murray , Xinjun Hou
IPC: C07D513/04 , C07D513/10 , C07D513/20
CPC classification number: C07D513/04 , C07D513/10 , C07D513/20
Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US20240245673A1
公开(公告)日：2024-07-25
申请号：US18532424
申请日：2023-12-07
Applicant: Pfizer Inc.
Inventor： James Matthew Frick , Michelle Renee Garnsey , Brian Stephen Gerstenberger , Xinjun Hou , Magdalena Korczynska , Alpha Albert Lee , Luong Tien Nguyen , Usa Reilly , Matthew Christopher Robinson , Alexandria Paige Taylor , Thomas Reynold Vargo , Lei Zhang
IPC: A61K31/4709 , A61K31/415 , A61K31/4178 , A61K31/4192 , A61K31/427 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K45/06 , C07D207/34 , C07D215/38 , C07D231/12 , C07D249/06 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/04 , C07D413/04 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/10 , C07D487/04 , C07D487/08 , C07D495/04
CPC classification number: A61K31/4709 , A61K31/415 , A61K31/4178 , A61K31/4192 , A61K31/427 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K45/06 , C07D207/34 , C07D215/38 , C07D231/12 , C07D249/06 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/04 , C07D413/04 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/10 , C07D487/04 , C07D487/08 , C07D495/04
Abstract: The invention relates to compounds of Formula (I)
and pharmaceutically acceptable salts thereof as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may inhibit the activity of papain-like protease (PLpro) and may be useful in the treatment of viral infections, in particular viral infections associated with PLpro activity and/or expression such as coronaviruses infections.-
公开(公告)号：US20240238425A1
公开(公告)日：2024-07-18
申请号：US18541015
申请日：2023-12-15
Applicant: Pfizer Inc.
Inventor： Jan Antoinette Cusi Romero Adams , Yotam Ashkenazi , Matthew Frank Brown , Jason Kenneth Dutra , Michelle Renee Garnsey , Xinjun Hou , Jisun Lee , Yajing Lian , Deane Milford Nason, II , Steven Victor O'Neil , Amanda Brooke Pecora , Alistair Dean Richardson , Matthew Forrest Sammons , Yang Wang , Ann Sorrentino Wright , Jun Xiao , Lei Zhang , Liying Zhang
Abstract: Described herein are 3-fluoro-4-hydroxybenzamide-containing inhibitors and/or degraders, and pharmaceutical compositions containing 3-fluoro-hydroxybenzamide-containing inhibitors and/or degraders. In some embodiments, the 3-fluoro-4-hydroxybenzamide-containing compounds of the disclosure can be used to treat a condition, for example, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
-
![N-[2-(2-Amino-6,6-Disubstituted-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-YL)-1,3-Thiazol-4-YL]Amides](/abs-image/US/2017/03/30/US20170088558A1/abs.jpg.150x150.jpg)
7.发明申请公开(公告)号：US20170088558A1
公开(公告)日：2017-03-30
申请号：US15272501
申请日：2016-09-22
Applicant: Pfizer Inc.
Inventor： Michael Aaron Brodney , Christopher Ryan Butler , Lei Zhang , Brian Thomas O'Neill , Patrick Robert Verhoest , Peter Justin Mikochik , John Charles Murray , Xinjun Hou
IPC: C07D513/04 , C07D513/20 , C07D513/10
CPC classification number: C07D513/04 , C07D513/10 , C07D513/20
Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1, R2 and R3 are as defined in the specification.Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
-
-
-
-
-
Search Results
7
records
(took 0.017 seconds)
